Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05240898 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumors, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 116
- Enrollment target
- 15
- Study locations
NCT05240898: Completed Phase 1 study of Advanced Solid Tumors, sponsored by Hoffmann-La Roche.
NCT05240898 is a Phase 1 study of Advanced Solid Tumors that has completed, run by Hoffmann-La Roche. The registered enrollment target is 116 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (41% lower). The trial reports 15 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05240898, a Phase 1 study of Advanced Solid Tumors, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 116 participants
- Enrollment target
- 15
- Study locations
Study Summary
This is a Phase 1 study to assess the safety and clinical activity of RO7623066 alone and in combination in patients with advanced solid tumors.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Olaparib
- DRUG RO7623066
Study Locations (15)
Texas
- Mary Crowley Medical Research Center - Dallas
- The University of Texas MD Anderson Cancer Center - Houston
- South Texas Accelerated Research Therapeutics (START) - San Antonio
Ohio
- Cleveland Clinic, - Cleveland
- The Ohio State University Comprehensive Cancer Center - Columbus
California
- University of California Irvine Medical Center - Orange
Connecticut
- Yale School of Medicine - New Haven
Maine
- Barbara Ann Karmanos Cancer Institute - Detroit
Massachusetts
- Dana-Farber Cancer Institute - Boston
Michigan
- South Texas Accelerated Research Therapeutics (START) - Midwest Location - Grand Rapids
New Jersey
- Hackensack University Medical Center - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2021-08-26 |
| Est. Completion | 2025-11-26 |
| Phase | Phase 1 |
What the finished NCT05240898 record still lists
NCT05240898 is an interventional study that assigns participants to a tested intervention. The registered 116 participants enrollment target is mid-sized for trials with a published cap, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (41% lower).
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 3 interventions - of which Carboplatin is the first listed.
NCT05240898 lists 15 locations in 12 states (Texas, Ohio, California).
Frequently Asked Questions
What is clinical trial NCT05240898 about?
NCT05240898 is a clinical study titled "A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors". This is a Phase 1 study to assess the safety and clinical activity of RO7623066 alone and in combination in patients with advanced solid tumors.
What is the current status of trial NCT05240898?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 116 participants. The study started on 2021-08-26. Estimated completion is 2025-11-26.
What conditions does trial NCT05240898 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT05240898?
The interventions under investigation include: Carboplatin (DRUG), Olaparib (DRUG), RO7623066 (DRUG).
Who is sponsoring clinical trial NCT05240898?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05240898 being conducted?
This trial has 15 study locations across California, Connecticut, Maine, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05240898's enrollment target sits among peer trials
116 74th of 144 higher than 70 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03014687 · 116 participants · Phase 4
Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions
- NCT03214562 · 116 participants · Phase 1
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
- NCT03847467 · 116 participants · Phase 1
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
- NCT04372615 · 116 participants · Phase 2
The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI